Literature DB >> 9305515

Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

B Winblad1, S Hill, B Beermann, S G Post, A Wimo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9305515

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN： 0893-0341            Impact factor:   2.703


× No keyword cloud information.
  5 in total

1.  Costs of Mini Mental State Examination-related cognitive impairment.

Authors:  L Jönsson; P Lindgren; A Wimo; B Jönsson; B Winblad
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

Review 2.  Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  H M Lamb; K L Goa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  Donepezil. Pharmacoeconomic implications of therapy.

Authors:  R H Foster; G L Plosker
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

4.  Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 5.  Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.

Authors:  Anders Wimo
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.